BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34576156)

  • 61. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
    Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
    Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The use of anterior segment optical coherence tomography (ASOCT) in demonstrating recurrence of vitreoretinal lymphoma (VRL) in the anterior vitreous.
    Diaconita V; Rihani H; Mares V; Nehemy MB; Bakri SJ; Pulido JS
    Int J Retina Vitreous; 2019; 5():19. PubMed ID: 31452937
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
    Kvopka M; Lake SR; Smith JR
    Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Analysis of genomic alterations in primary central nervous system lymphoma.
    He X; Fan X; Shan Y; Ji X; Su L; Wang Y
    Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032
    [TBL] [Abstract][Full Text] [Related]  

  • 65. USE OF A THRESHOLD OF INTERLEUKIN-10 AND IL-10/IL-6 RATIO IN OCULAR SAMPLES FOR THE SCREENING OF VITREORETINAL LYMPHOMA.
    Pochat-Cotilloux C; Bienvenu J; Nguyen AM; Ohanessian R; Ghesquières H; Sève P; Garnier L; Kodjikian L
    Retina; 2018 Apr; 38(4):773-781. PubMed ID: 29135797
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma.
    Rahhal-Ortuño M; Udaondo-Mirete P; Fernández-Santodomingo AS; Díaz-Llopis M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP199-NP202. PubMed ID: 32985253
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CXCR4, CXCR5 and CD44 May Be Involved in Homing of Lymphoma Cells into the Eye in a Patient Derived Xenograft Homing Mouse Model for Primary Vitreoretinal Lymphoma.
    Babst N; Isbell LK; Rommel F; Tura A; Ranjbar M; Grisanti S; Tschuch C; Schueler J; Doostkam S; Reinacher PC; Duyster J; Kakkassery V; von Bubnoff N
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233057
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relationship between vitreoretinal lymphoma and the site of lymphoma development in the central nervous system.
    Maruyama K; Iwahashi C; Hashida N; Ohguro N; Nishida K
    Jpn J Ophthalmol; 2022 Mar; 66(2):142-150. PubMed ID: 34860298
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
    Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
    Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
    BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.
    Belhouachi N; Xochelli A; Boudjoghra M; Lesty C; Cassoux N; Fardeau C; Tran THC; Choquet S; Sarker B; Houillier C; Alentorn A; LeHoang P; Soussain C; Touitou V; Merle-Beral H; Hoang-Xuan K; Bodaghi B; Stamatopoulos K; Davi F
    Blood Adv; 2020 Apr; 4(7):1357-1366. PubMed ID: 32267931
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma.
    Pichi F; Dolz-Marco R; Francis JH; Au A; Davis JL; Fawzi A; Gattousi S; Goldstein DA; Keane PA; Miserocchi E; Marchese A; Ohno-Matsui K; Sagoo MS; Smith SD; Sobol EK; Tasiopoulou A; Yang X; Shields CL; Freund KB; Sarraf D
    Am J Ophthalmol; 2022 Jun; 238():16-26. PubMed ID: 34843686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness of digital PCR for MYD88
    Chen K; Ma Y; Ding T; Zhang X; Chen B; Guan M
    Exp Ther Med; 2020 Jul; 20(1):301-308. PubMed ID: 32536998
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serial Detection of
    Choi S; Shin S; Lee ST; Lee J; Lee JS; Kim B; Lee CS
    Ocul Immunol Inflamm; 2021 Apr; 29(3):485-489. PubMed ID: 32965155
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.
    Bonzheim I; Giese S; Deuter C; Süsskind D; Zierhut M; Waizel M; Szurman P; Federmann B; Schmidt J; Quintanilla-Martinez L; Coupland SE; Bartz-Schmidt KU; Fend F
    Blood; 2015 Jul; 126(1):76-9. PubMed ID: 25900979
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
    Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of vitreous cytology in the diagnosis of primary central nervous system lymphoma: A report of an unusual presentation.
    Tom JP; Gupta P; Radotra BD; Gupta N; Takkar A; Singh S; Gupta V
    Diagn Cytopathol; 2023 Aug; 51(8):E232-E238. PubMed ID: 37148480
    [TBL] [Abstract][Full Text] [Related]  

  • 79. More Accurate Diagnosis of Vitreoretinal Lymphoma Using a Combination of Diagnostic Test Results: A Prospective Observational Study.
    Tanaka R; Kaburaki T; Taoka K; Karakawa A; Tsuji H; Nishikawa M; Yatomi Y; Shinozaki-Ushiku A; Ushiku T; Araki F
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1354-1360. PubMed ID: 33793360
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
    Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
    Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.